

Response

2
The Department may, at its discretion, publish part or all of the information provided in your submission on the Department's website or in related documents. If information from your submission is published, the Department may identify you and/or your organisation as the author of the submission. All personal contact details will be removed prior to publishing.
Yes, I consent to my identified submission being published

3
What is your name?
Eric Johnsson

7
Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Selected Choice
Pharmaceutical / Medical technology company

8.1
What is the name of your organisation? - My organisation is called: - Text
GSK

9
Are you making feedback on behalf of your organisation?
Your organisation

13
Please select which chapter/s you would like to provide feedback on. You may provide feedback on as many or few chapters as you wish.
1. Transparency, communication, and stakeholder involvement in HTA,2. Health technology funding and assessment pathways,3. Methods for HTA for Australian government subsidy (technical methods),4. Health technology funding and purchasing approaches and managing uncertainty,5. Futureproofing Australia's systems and processes

14
Please select the topics within the chapter(s) you would like to provide feedback on. 1. Transparency, communication and stakeholder involvement in HTA
1.1. Transparency and communication of HTA pathways, processes and decisions,1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA,1.3. First Nations people involvement and consideration in HTA,1.4. State and territory government collaboration in HTA

15
Please select the topics within the chapter(s) you would like to provide feedback on. 2. Health technology funding and assessment pathways
2.1. Streamlining and aligning HTA pathways and advisory committees,2.2. Proportionate appraisal pathways

16
Please select the topics within the chapter(s) you would like to provide feedback on. 3. Methods for HTA for Australian government subsidy (technical methods)
3.1. Determination of the Population, Intervention, Comparator, Outcome,3.2. Clinical Evaluation Methods,3.3. Economic evaluation

17
Please select the topics within the chapter(s) you would like to provide feedback on. 4. Health Technology funding and purchasing mechanisms and decisions
4.1. Approaches to funding or purchasing new health technologies,4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR),4.3. Understanding the performance of health technologies in practice

18
Please select the topics within the chapter(s) you would like to provide feedback on. 5. Futureproofing our systems and processes
5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS,5.2. Establishment of horizon scanning programs to address specific informational needs within HTA and the health system,5.3. Consideration of environmental impacts in the HTA,5.4. Mechanisms for continuous review and improvement,5.5. Capacity and capability of the HTA system,5.6. Strengthen international partnerships and work-sharing

21
Taking all Options within this section: 1.1. Transparency, communication and stakeholder involvement in HTA into account.
Overall, to what extent could the options (if implemented) address the issues that relate to them?
Mostly address the issue(s)

22
If you would like to expand on your answer above you can do so below:
GSK supports increased transparency, while noting it is important to maintain the confidentiality of commercially sensitive information.

23.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Publish plain language summaries
Positive

23.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Improvements to the HTA webpage including development of a dashboard
Positive

27
Taking all Options within this section: 1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA into account.
Overall, to what extent could the options (if implemented) address the issues that relate to them?
Address some but not most of the issue(s)

28
If you would like to expand on your answer above you can do so below:
Stakeholder consultation is critical to guide Options.

29.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Develop an engagement framework
Positive

29.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Strengthen consumer evidence
Positive

33
Taking all Options within this section: 1.3. First Nations people involvement and consideration in HTA into account.
Overall, to what extent could the options (if implemented) address the issues that relate to them?
Mostly address the issue(s)

35.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - First Nations peoples partnership in decision making
Positive

35.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Dedicated resource for HTA submissions and education
Positive

39
Taking all Options within this section: 1.4. State and territory government collaboration in HTA into account.
Overall, to what extent could the options (if implemented) address the issues that relate to them?
Mostly address the issue(s)

41.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Development of central standardised data sharing system for utilisation and outcome data
Neutral

41.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Increase opportunities for consultation and work sharing
Neutral

41.3
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Health technologies that are jointly funded by the Commonwealth and state and territory governments (such as high cost, Highly Specialised Therapies (HSTs) delivered to public hospital inpatients)
Neutral

46
Taking all Options within this section: 2.1. Streamlining and aligning HTA pathways and advisory committees into account.
Overall, to what extent could the options (if implemented) address the issues that relate to them?
Address little or none of the issue(s)

48.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))
Neutral

48.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Vaccine pathway
Very negative

48.3
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Expanding role of PBAC
Negative

48.4
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Unified HTA pathway for all health technologies with Commonwealth funding
Negative

60
If you would like to expand on your answer above you can do so below -Vaccine pathway
Do not progress 2.1: Vaccine pathway option 1 as proposed. Streamline process while retaining the comprehensive independent input of the Australian Technical Advisory Group on Immunisation (ATAGI), recognising the value of vaccines on patient outcomes.

63
Taking all Options within this section: 2.2. Proportionate appraisal pathways into account
Overall, to what extent could the options (if implemented) address the issues that relate to them?
Address little or none of the issue(s)

65.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Case manager
Neutral
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Triaging submissions

Negative
65.2 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Streamlined pathway for cost-minimisation submissions (therapies not claiming a significant improvement in health outcomes or reduction in toxicity)
Negative
65.3 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN:
Alternative option 1: Introducing an optional resolution step before HTA committee consideration
Negative
65.4 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN:
Alternative option 2: Introducing an optional resolution step before HTA committee consideration, with additional post committee resolution
Negative
65.5 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN:
Alternative option 3: Early Price negotiation
Negative
65.6 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN:
Alternative option 4: Introducing an optional resolution step after HTA committee consideration but before advice is finalised
Neutral
65.7 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Expanding resolution step to all relevant cost effectiveness submissions
Neutral
65.8 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Development of a disease specific common model (reference case) for disease areas with high active product development
Negative
65.9 If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Decouple the requirement for the TGA Delegate's overview to support PBAC advice
Positive
69 If you would like to expand on your answer above you can do so below -Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN
Alternative option 1: Introducing an optional resolution step before HTA committee consideration It is unclear whether an increased role of the ESC in Alternative Options 1-3 will assist the decision-making capacity for the PBAC. One of the most critical aspects of the ESC advice is whether the structure of the economic model is reliable for the PBAC's decision making. GSK has experienced situations where a model has been deemed reliable for decision making but resulted in a rejection, and the opposite situation where a model deemed unreliable has resulted in a PBAC recommendation.
70